As of Jan 20
| +0.20 / +1.29%|
The 13 analysts offering 12-month price forecasts for Myriad Genetics Inc have a median target of 18.00, with a high estimate of 42.00 and a low estimate of 15.00. The median estimate represents a +14.94% increase from the last price of 15.66.
The current consensus among 17 polled investment analysts is to Hold stock in Myriad Genetics Inc. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.